Pharma


  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J sees mixed performance from new multiple myeloma drugs

    Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."

    By April 16, 2024
  • Man discusses neck pain with female physician
    Image attribution tooltip
    SDI Productions via Getty Images
    Image attribution tooltip
    Sponsored by Sysmex Inostics

    The growing role for cfHPV-DNA testing in OPSCC therapeutic development

    Learn about why access to robust biomarkers such as cfHPV-DNA is pivotal in determining eligibility, assessing treatment response and detecting recurrence early to improve patient outcomes.

    April 15, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Blog
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Blog

    A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?

    By BioPharma Blog staff
  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex to buy kidney disease drugmaker Alpine for $4.9B

    A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.

    By Updated April 11, 2024
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip
    RSV vaccines

    Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59

    The company plans to submit the trial data to regulators in a bid to win approval of its vaccine Abrysvo in adults as young as 18 years old.

    By April 9, 2024
  • A person wearing a white coat works at a research laboratory bench.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Deep Dive

    Psychiatry drugs finally have pharma’s attention. Can they keep it?

    Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

    By April 8, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    Boehringer Ingelheim to lay off staff amid biosimilar challenges

    The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

    By April 5, 2024
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use

    The FDA quickly followed last week’s clearance of Bristol Myers’ Abecma with an OK for J&J’s Carvykti, but gave the rival treatments different labels.

    By Updated April 8, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck puts KRAS cancer drug competitor to the test

    A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

    By April 4, 2024
  • Virus cells under a microscope.
    Image attribution tooltip

    stock.adobe.com/TensorSpark

    Image attribution tooltip
    Sponsored by Advanced Clinical

    Breaking barriers: Advances and challenges in therapeutic cancer vaccines

    The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.

    By Christopher Oelkrug, Director of Business Development • April 1, 2024
  • Image attribution tooltip
    National Cancer Institute, NIH
    Image attribution tooltip

    Bristol Myers says KRAS drug succeeds in key trial

    Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.

    By March 29, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche autoimmune disease drug disappoints in closely watched trial

    Though the medicine hit its goal in a Phase 3 study in myasthenia gravis, the results fell short of expectations in a boost to rival drug developers like Argenx and AstraZeneca.

    By March 21, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer streamlines pharma leadership team amid company shakeup

    The executive team will reportedly shrink from 14 to eight in the latest step in new CEO Bill Anderson’s plan to slash management and reduce “bureaucracy” at the healthcare conglomerate.

    By Kristin Jensen • March 21, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    With new data, Bayer readies rival to Astellas menopause drug

    Following a third successful Phase 3 trial, the company is planning approval filings for the medicine, which it acquired in a $425 million deal four years ago.

    By March 19, 2024
  • Prostate cancer cells, 3D illustration. Prostate cancer awareness image
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion

    The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.

    By March 19, 2024
  • Doctor hands texting on a smart phone
    Image attribution tooltip

    shutterstock.com/VAlekStudio

    Image attribution tooltip
    Sponsored by Veeva

    Give HCPs a proactive way to reach your field team: Add inbound

    HCPs today want inbound channels for help when they need it. See how you can meet their preferences.

    By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers cell therapy wins first-of-its-kind approval

    Sold as Breyanzi, the therapy is now cleared for use in certain adults with hard-to-treat forms of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

    By March 15, 2024
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt

    The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.

    By Kristin Jensen • March 14, 2024
  • A scientific illustration of amyloid plaques and neurons, colored in blue and orange.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Roche, following setbacks, turns to its next Alzheimer’s drug

    Roche said its experimental Alzheimer’s disease drug trontinemab showed it might be able to clear brain plaques faster than other medicines.

    By March 11, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J’s growing rare disease focus brings a potential multi-use treatment to the table

    The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.

    By Michael Gibney • March 11, 2024
  • A Lilly sign is seen on the side of a building viewed through pine trees
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    FDA delays decision on Lilly’s closely watched Alzheimer’s drug

    The agency expects to convene a group of outside experts to more closely scrutinize the safety and efficacy of the medicine, donanemab, pushing back the timing of its potential approval.

    By March 8, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer isn’t splitting up, for now

    Company shares fell after executives disclosed plans to, at least temporarily, keep its three main divisions under one roof.

    By March 5, 2024
  • Orange packages of mifepristone tablets rest against each other on a table.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    CVS, Walgreens to start selling abortion pill in some states

    The two pharmacy retailers will begin dispensing mifepristone in some states weeks before the start of a Supreme Court case that will decide how widely the pill can be accessed.

    By March 4, 2024
  • Judge gavel and pills against blue backdrop
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    AstraZeneca’s drug pricing lawsuit dismissed by federal judge

    The rejection is the latest setback in the pharmaceutical industry’s efforts to use the courts to challenge Medicare’s new pricing powers.

    By March 4, 2024
  • human heart
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Bayer pays $310M to buy into BridgeBio heart drug

    The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.

    By March 4, 2024
  • A data scientist developing a machine learning model using AI.
    Image attribution tooltip

    Adobe Stock / yj

    Image attribution tooltip
    Sponsored by Panalgo

    Q&A: How AI and ML are reshaping the research landscape

    Panalgo’s Meg Richards and Mike Munsell discuss how AI and ML are transforming the healthcare research landscape.

    By Meg Richards, PhD, MBH Executive Director of Solutions, Panalgo With Mike Munsell, Director of Research, Panalgo • March 4, 2024